Open AccessShort-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
Author(s) -
Davide Allegrini,
Raffaele Raimondi,
Giovanni Montesano,
Alfredo Borgia,
Tania Sorrentino,
Panagiotis Tsoutsanis,
Mario R. Romano
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s323058
Subject(s) - medicine , macular degeneration , ophthalmology , visual acuity , covid-19 , bevacizumab , retrospective cohort study , retinal pigment epithelium , retinal , surgery , disease , chemotherapy , infectious disease (medical specialty)
To assess outcomes and recovery strategy of patients undergoing intravitreal injections for exudative age-related macular degeneration who experienced COVID-19 related interruption in treatment during complete lockdown.